The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and for weight loss, may be linked with a reduced risk of substance use and neurocognitive disorders, a US study in people ...

One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for ...

This cross-sectional study showed websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially informed and sometimes misinformed potential consumers. Compounded ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Most people have missed a dose of prescription medication at some point. But if you are taking a glucagon-like peptide-1 drug ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

“Alright, I have a confession to make. Yes, I am on a GLP-1 for a weight-loss medication,” Van Ness said.

Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level Mr. Shah Coherent Market Insights Pvt.

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

It may lower the risk of heart and blood disorders such as deep vein thrombosis and heart attack, as well as neurocognitive ...